Scilex Holding (SCLX) Other Accumulated Expenses (2020 - 2026)
Scilex Holding (SCLX) posted quarterly Other Accumulated Expenses of $247.5 million for Q1 2026, up 46.95% year-over-year from $168.4 million in Q1 2025, and up 7485.47% quarter-over-quarter from $3.3 million in Q4 2025.
Scilex Holding (SCLX) Other Accumulated Expenses (2020 - 2026) Analysis & Trends
Scilex Holding's Other Accumulated Expenses history runs 7 years deep, the most recent figure standing at $247.5 million for Q1 2026.
- In Q1 2026, Other Accumulated Expenses rose 46.95% year-over-year to $247.5 million; the TTM figure through Mar 2026 stood at $247.5 million (up 46.95% YoY), while the FY2025 annual figure was $3.3 million, down 97.99% from the prior year.
- Other Accumulated Expenses for Q1 2026 stood at $247.5 million, up from $3.3 million in the prior quarter.
- The five-year high for Other Accumulated Expenses was $247.5 million in Q1 2026, with the low at $3.3 million in Q4 2025.
- The 5-year median for Other Accumulated Expenses is $114.6 million (2024), against an average of $116.3 million.
- The sharpest annual moves came in 2022 and 2025: Other Accumulated Expenses surged 319.63% in 2022, then plunged 97.99% in 2025.
- Scilex Holding's Other Accumulated Expenses stood at $30.9 million in 2022, then jumped by 190.22% to $89.7 million in 2023, then surged by 81.26% to $162.5 million in 2024, then slumped by 97.99% to $3.3 million in 2025, then jumped by 7485.47% to $247.5 million in 2026.
- Business Quant data shows SCLX's Other Accumulated Expenses at $247.5 million in Q1 2026, $3.3 million in Q4 2025, and $213.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Scilex Holding | 39.22 Mn | -73.57 Mn | 3.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 247.51 Mn |
| Dec 31, 2025 | 3.26 Mn |
| Sep 30, 2025 | 213.38 Mn |
| Jun 30, 2025 | 192.94 Mn |
| Mar 31, 2025 | 168.43 Mn |
| Dec 31, 2024 | 162.52 Mn |
| Sep 30, 2024 | 141.71 Mn |
| Jun 30, 2024 | 125.06 Mn |
| Mar 31, 2024 | 104.09 Mn |
| Dec 31, 2023 | 89.66 Mn |
| Sep 30, 2023 | 65.80 Mn |
| Jun 30, 2023 | 47.78 Mn |
| Mar 31, 2023 | 35.63 Mn |
| Dec 31, 2022 | 30.89 Mn |
| Dec 31, 2021 | 7.36 Mn |
| Dec 31, 2020 | 25,760.00 |